Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

HumanNeuronScreen

Financiado

Drug discovery screening using human neurons

Brain disorders present a staggering health-care burden, costing around 800 billion euros per year in the EU and affecting almost 180 million people. Currently, development of treatments for these disorders is very unsuccessful. O... ver más

30/04/2022

STICHTING AMSTERDA...

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

STICHTING AMSTERDAM UMC No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-04-30

ERC-2020-POC: Call for proposals for ERC Proof of...

I+D

Cerrada hace 4 años

0% 100% 100%

2 Participantes

STICHTING AMSTERDAM UMC

150.00K€ | Lider

FERSINT FERRICOS SINTERIZADO...

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

EQC2019-005809-P Actualización de la Plataforma para el Estudio de la Conduct... 79K€ Cerrado

EQC2018-005332-P Detección precoz de enfermedades neurodegenerativas con inmu... 67K€ Cerrado

RED2018-102499-T LA RETINA UN MODELO PARA INVESTIGAR NEUROPROTECCION EN PATOL... 20K€ Cerrado

CTQ2011-29163-C03-01 ELECTROCHEMICAL IMMUNOSENSOR SYSTEM FOR THE DETECTION OF NEU... 110K€ Cerrado

AGEMEC Age dependent mechanisms of sporadic Alzheimer s Disease in... 1M€ Cerrado

CTQ2015-68380-R NUEVAS MOLECULAS MULTIDIANA Y TERANOSTICAS PARA EL DIAGNOSTI... 155K€ Cerrado

Duración del proyecto: 18 meses Fecha Inicio: 2020-10-27
Fecha Fin: 2022-04-30

Líder del proyecto

STICHTING AMSTERDAM UMC No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto Brain disorders present a staggering health-care burden, costing around 800 billion euros per year in the EU and affecting almost 180 million people. Currently, development of treatments for these disorders is very unsuccessful. Of all currently prescribed drugs, >30% target G-protein coupled receptors, that are typically activated by neuromodulators. Neuromodulators are signaling molecules secreted by most neurons, which regulate many processes in our brain and body. Dysregulation of neuromodulator secretion is firmly associated with many neuropsychiatric disorders, but no screening assay for neuromodulator secretion is currently available to test drug candidates. We have developed a human-based neuromodulator screening assay for preclinical testing of compounds for neuropsychiatric disorders. This assay, the HumanNeuronScreen, uses human neurons derived from somatic patient cells (e.g. skin), to maximally approach the situation in the patients’ CNS and thereby greatly enhancing target validation and lead optimization in preclinical research. It delivers in depth knowledge on the mechanism, potency and selectivity of drug candidates, supporting a higher success rate for clinical trials. Therefore, the value proposition of our product consists of a drastic reduction of costs in drug-development for pharmaceutical and biotech companies, and potentially impacts on 180 million patients in Europe. This proof-of-concept project aims to prove the commercial potential for the HumanNeuronScreen by measuring a reference library of compounds that establishes the resolution, reproducibility and dynamic range of the screen. An IP strategy will be developed to ensure a market position and business strategy will be created and validated. Together, this maximizes the value of the research conducted in the ERC Advanced grant DCV fusion.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores